Intended for UK Healthcare Professionals only. Adverse Event Reporting information can be found at the bottom of the page.
This website contains promotional information

Medikinet® (methylphenidate hydrochloride) tablets

Medikinet® tablets can be used as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children aged 6 years of age and over when remedial measures alone have proved insufficient. 1 Medikinet tablets are not licensed for use in adults 18yrs and over.

Dosing & administration

  • At the start of treatment with Medikinet® tablets, careful dose titration is necessary 1
  • Recommended starting daily dose is 5 mg once or twice daily e.g. at mealtimes 1
  • Dose can be increased if necessary by weekly increments of 5-10 mg daily, depending on how well it’s tolerated and working. The maximum daily dose of methylphenidate hydrochloride is 60 mg. 1
  • When treating ADHD, it helps to carefully choose the time treatment is taken so it combats any school or behavioural difficulties most effectively 1

Safety and Monitoring

For full safety and monitoring information please refer to section 4 of the SmPC or click here.

Contact us

If you would like to find out more about our treatments or therapy area expertise, please contact us

  1. Medikinet® tablets, Summary of Product Characteristics.

Medikinet® XL

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at the Yellow Card Scheme; or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK at
Please retain the reported medication and packaging for further investigation by MEDICE UK.
Reporting side effects can provide more information on the safety of this medicine.